Skip to content

Dapagliflozin and Metformin

Dapagliflozin and Metformin comes in 36 pill versions in our database, in 8 strengths, from 11 manufacturers. Check the imprint to tell them apart.

Dapagliflozin and Metformin pill images

2.5 mg / 1000 mg 1 pill

5 mg / 500 mg 7 pills

5 mg / 850 mg 1 pill

5 mg / 1000 mg 9 pills

10 mg / 500 mg 8 pills

10 mg / 1000 mg 8 pills

850 mg / 5 mg 1 pill

1000 mg / 5 mg 1 pill

What is Dapagliflozin and Metformin used for?

Dapagliflozin and Metformin is used for type 2 diabetes and heart failure.

Medicine type
Diabetes medicine (SGLT2 inhibitor); diabetes medicine (biguanide)
Official uses from the US prescribing label

Dapagliflozin and metformin hydrochloride extended-release tablets are a combination of dapagliflozin and metformin hydrochloride (HCl) extended-release, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Dapagliflozin, when used as a component of dapagliflozin and metformin hydrochloride extended-release tablets, is indicated in adults with type 2 diabetes mellitus to reduce the risk of:

  • Sustained eGFR decline, end-stage kidney disease, cardiovascular (CV) death, and hospitalization for heart failure in patients with chronic kidney disease at risk of progression.
  • CV death, hospitalization for heart failure, and urgent heart failure visit in patients with heart failure.
  • Hospitalization for heart failure in patients with type 2 diabetes mellitus and either established CV disease or multiple CV risk factors.

Limitations of Use

  • Dapagliflozin and metformin hydrochloride extended-release tablets are not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus.
  • Because of the metformin hydrochloride component, the use of dapagliflozin and metformin hydrochloride extended-release tablets is limited to patients with type 2 diabetes mellitus for all indications.
  • Dapagliflozin and metformin hydrochloride extended-release tablets are not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. Dapagliflozin and metformin hydrochloride extended-release tablets are not expected to be effective in these populations.

Pediatric use information is approved for AstraZeneca AB’s Xigduo ® XR (dapagliflozin and metformin hydrochloride) Extended-Release Tablets. However, due to AstraZeneca AB’s marketing exclusivity rights, this drug product is not labeled with that information.

From the FDA-approved label on DailyMed (published Sep 24, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.